Core Viewpoint - A class action securities lawsuit has been filed against WPP plc, alleging securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1][2] Company Performance - The lawsuit claims that WPP's management provided overly positive statements while concealing material adverse facts about the company's media arm, which was struggling to cope with macroeconomic challenges and losing market share [2] - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainty affecting client spending and weaker new business than expected, partly due to ongoing restructuring within WPP Media (GroupM) [2] - Following the trading update, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking a decline of approximately 18.1% in one day [2] Legal Proceedings - Investors who suffered losses during the specified period have until December 8, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4]

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

Core Viewpoint - Cytokinetics, Incorporated is facing a class action lawsuit due to allegations of misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, which has led to significant losses for investors [3][4]. Summary by Sections Allegations - The complaint claims that Cytokinetics made materially false and misleading statements about the expected timeline for FDA approval of aficamten, initially projected for the second half of 2025 based on a PDUFA date of September 26, 2025 [3]. - It is alleged that the company failed to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [3]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA regarding safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [3]. Impact on Shareholders - As a result of the misleading statements, shareholders purchased Cytokinetics' common stock at artificially inflated prices and experienced significant losses when the truth was disclosed [3]. Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, with a deadline for shareholders to register for the class action set for November 17, 2025 [4]. - Shareholders who register will receive updates on the case's status and can participate without any cost or obligation [4]. Law Firm Information - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [5].

Core Insights - Cytokinetics, Incorporated is facing a securities fraud class action lawsuit due to alleged misleading statements regarding drug development timelines [1][3][6] - The lawsuit claims that the company failed to disclose a Risk Evaluation and Mitigation Strategy (REMS) in their New Drug Application (NDA), leading to delays in FDA approval [2][3] - Financially, Cytokinetics shows a negative price-to-earnings (P/E) ratio of -11.38 and a high price-to-sales ratio of 80.64, indicating challenges in profitability and valuation [4][5][6] Legal Issues - The class action lawsuit is open to investors who suffered losses from misleading statements made between December 27, 2023, and May 6, 2025 [3] - Investors have until November 17, 2025, to join the lawsuit [3] Financial Performance - The company has a current ratio of 6.76, suggesting a strong ability to cover short-term liabilities [5][6] - However, the negative debt-to-equity ratio of -2.33 indicates that liabilities exceed equity, highlighting financial risks [5]

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("Nutex Health Inc." or the "Company") (NASDAQ: NUTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/nutex-h ...

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Semler Scientific, Inc. ("Semler Scientific, Inc." or the "Company") (NASDAQ: SMLR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Semler Scientific, Inc. investors who were adversely affected by alleged securities fraud between March 10, 2021 and April 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by alleged securities fraud between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made materially false statements regarding the NDA submission timeline and FDA approval expectations, claiming approval in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - The complaint highlights that the company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. Group 2: Impact on Investors - On May 6, 2025, it was revealed during an earnings call that Cytokinetics had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. - As a result of the misleading statements, investors purchased Cytokinetics' common stock at inflated prices and suffered significant losses when the truth was disclosed [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until November 17, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

Core Insights - F5, Inc. is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and unlawful business practices [1][3] - The investigation follows a security breach where a nation-state threat actor gained unauthorized access to F5 systems, leading to the exfiltration of sensitive files, including portions of the BIG-IP source code [3] - Following the announcement of the breach, F5's stock price dropped by $35.40, approximately 10.70%, from $330.75 to $295.35 [3] Investigation Details - The breach was discovered in early August 2025, with the threat actor maintaining long-term access to F5 systems [3] - The compromised systems included the BIG-IP product development environment and engineering knowledge management platform [3] - The exfiltrated files contained information about undisclosed vulnerabilities that F5 was addressing in its BIG-IP product [3] Next Steps for Investors - Investors who acquired F5 securities or have relevant information are encouraged to contact Kirby McInerney LLP for further discussion regarding their rights or interests [4]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in KBR, Inc. of, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shar ...